Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

U.S. leads drug-approval race

By Drug Discovery Trends Editor | May 17, 2012

The U.S. Food and Drug Administration (FDA)
generally approves drug therapies faster and earlier than its counterparts in Canada and Europe,
according to a new study by Yale University School of Medicine researchers. The
study counters perceptions that the drug approval process in the U.S. is
especially slow.

Led by second-year medical student Nicholas
Downing and senior author Dr. Joseph S. Ross, assistant professor of internal
medicine at Yale School of Medicine, the study will be published by the New England Journal of Medicine.

Regulatory review represents the final step
in the process of bringing new medical technologies from the laboratory to the
bedside. Efficient regulatory review processes may enable patients to get
access to promising new therapies sooner, while ensuring drug safety.

“The perception that the FDA is too slow
implies that sick patients are waiting unnecessarily for regulators to complete
their review of new drug applications,” said Downing, who decided to conduct
the study because there have been no recent comparisons of the FDA’s regulatory
review speed with those of regulating agencies in other countries.

Downing, Ross, and colleagues reviewed drug
approval decisions of the FDA; the Canadian drug regulator, Health Canada; and the
European Medicines Agency (EMA) between 2001 and 2010. They studied each
regulator’s database of drug approvals to identify novel therapeutics as well
as the timing of key regulatory events, allowing regulatory review speed to be
calculated. Canada and Europe were chosen as a comparison because they face
similar pressures to approve new drugs quickly while ensuring they do not put
patients at risk.

The team found that the median total time
to review was 322 days at FDA, 366 days at EMA, and 393 days at Health Canada.

“Among the subsample of drugs approved for
all three regulators, the FDA’s reviews were over three months faster than
those of the EMA or Health Canada,”
said Downing. “The total review time at the FDA was faster than EMA, despite
the FDA’s far higher proportion of applications requiring multiple regulatory
reviews.”

Downing
added that most new drug therapies were first approved for use in the U.S. “Examining novel drugs approved in multiple markets, we found that 64% of
medicines approved in both the U.S. and in Europe were approved for U.S.
patients first, and 86% of medicines approved in both the U.S. and Canada were
also approved first in the U.S.,” he said.

Yale University


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE